Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
Identifieur interne : 000139 ( Main/Corpus ); précédent : 000138; suivant : 000140Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
Auteurs : Ricardo Pereda ; Daniel González ; Hubert Blas Rivero ; Juan Carlos Rivero ; Albadio Pérez ; Lissette Del Rosario L Pez ; Natacha Mezquia ; Rafael Venegas ; Julio Roberto Betancourt ; Rodolfo Emilio DomínguezSource :
- Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research [ 1557-7465 ] ; 2020.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Child (MeSH), Child, Preschool (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (mortality), Cuba (MeSH), Drug Therapy, Combination (MeSH), Female (MeSH), Humans (MeSH), Infant (MeSH), Interferon-alpha (therapeutic use), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (mortality), Prospective Studies (MeSH), Ritonavir (therapeutic use), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Chloroquine, Interferon-alpha, Lopinavir, Ritonavir.
- geographic : Cuba.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Infant, Male, Middle Aged, Pandemics, Prospective Studies, Young Adult.
Abstract
A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus disease 2019 (COVID-19) outbreak began in Cuba. From March 11th to April 14th, 814 patients were confirmed SARS-CoV-2 positive in Cuba. Seven hundred sixty-one (93.4%) were treated with a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-α2b (Heberon® Alpha R, Center for Genetic Engineering and Biotechnology, Havana, Cuba), 3 times per week, for 2 weeks. Fifty-three patients received the approved COVID protocol without IFN treatment. The proportion of patients discharged from hospital (without clinical and radiological symptoms and nondetectable virus by real-time polymerase chain reaction) was higher in the IFN-treated compared with the non-IFN treated group (95.4% vs. 26.1%, P < 0.01). The case fatality rate (CFR) for all patients was 2.95%, and for those patients who received IFN-α2b the CFR was reduced to 0.92. Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-α2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients.
DOI: 10.1089/jir.2020.0124
PubMed: 32960147
Links to Exploration step
pubmed:32960147Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.</title><author><name sortKey="Pereda, Ricardo" sort="Pereda, Ricardo" uniqKey="Pereda R" first="Ricardo" last="Pereda">Ricardo Pereda</name><affiliation><nlm:affiliation>Intensive Medicine Department, Medical College of Havana, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, Daniel" sort="Gonzalez, Daniel" uniqKey="Gonzalez D" first="Daniel" last="González">Daniel González</name><affiliation><nlm:affiliation>Internal Medicine Department, Pedro Kouri Institute, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Rivero, Hubert Blas" sort="Rivero, Hubert Blas" uniqKey="Rivero H" first="Hubert Blas" last="Rivero">Hubert Blas Rivero</name><affiliation><nlm:affiliation>Internal Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Rivero, Juan Carlos" sort="Rivero, Juan Carlos" uniqKey="Rivero J" first="Juan Carlos" last="Rivero">Juan Carlos Rivero</name><affiliation><nlm:affiliation>Intensive Medicine Department, Miguel Enríquez Surgical Clinical Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Perez, Albadio" sort="Perez, Albadio" uniqKey="Perez A" first="Albadio" last="Pérez">Albadio Pérez</name><affiliation><nlm:affiliation>Intensive Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="L Pez, Lissette Del Rosario" sort="L Pez, Lissette Del Rosario" uniqKey="L Pez L" first="Lissette Del Rosario" last="L Pez">Lissette Del Rosario L Pez</name><affiliation><nlm:affiliation>Intensive Medicine Department, Juan Manuel Marquez Pediatric Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Mezquia, Natacha" sort="Mezquia, Natacha" uniqKey="Mezquia N" first="Natacha" last="Mezquia">Natacha Mezquia</name><affiliation><nlm:affiliation>Intensive Medicine Department, Miguel Enríquez Surgical Clinical Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Venegas, Rafael" sort="Venegas, Rafael" uniqKey="Venegas R" first="Rafael" last="Venegas">Rafael Venegas</name><affiliation><nlm:affiliation>Intensive Medicine Department, Luis Díaz Soto Central Military Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Betancourt, Julio Roberto" sort="Betancourt, Julio Roberto" uniqKey="Betancourt J" first="Julio Roberto" last="Betancourt">Julio Roberto Betancourt</name><affiliation><nlm:affiliation>Intensive Medicine Department, Manuel Piti Fajardo Surgical Clinical Military Hospital, Villa Clara, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Dominguez, Rodolfo Emilio" sort="Dominguez, Rodolfo Emilio" uniqKey="Dominguez R" first="Rodolfo Emilio" last="Domínguez">Rodolfo Emilio Domínguez</name><affiliation><nlm:affiliation>Intensive Medicine Department, Octavio de la Concepcion y la Pedraja Military Hospital. Camagüey, Cuba.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32960147</idno><idno type="pmid">32960147</idno><idno type="doi">10.1089/jir.2020.0124</idno><idno type="wicri:Area/Main/Corpus">000139</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000139</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.</title><author><name sortKey="Pereda, Ricardo" sort="Pereda, Ricardo" uniqKey="Pereda R" first="Ricardo" last="Pereda">Ricardo Pereda</name><affiliation><nlm:affiliation>Intensive Medicine Department, Medical College of Havana, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, Daniel" sort="Gonzalez, Daniel" uniqKey="Gonzalez D" first="Daniel" last="González">Daniel González</name><affiliation><nlm:affiliation>Internal Medicine Department, Pedro Kouri Institute, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Rivero, Hubert Blas" sort="Rivero, Hubert Blas" uniqKey="Rivero H" first="Hubert Blas" last="Rivero">Hubert Blas Rivero</name><affiliation><nlm:affiliation>Internal Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Rivero, Juan Carlos" sort="Rivero, Juan Carlos" uniqKey="Rivero J" first="Juan Carlos" last="Rivero">Juan Carlos Rivero</name><affiliation><nlm:affiliation>Intensive Medicine Department, Miguel Enríquez Surgical Clinical Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Perez, Albadio" sort="Perez, Albadio" uniqKey="Perez A" first="Albadio" last="Pérez">Albadio Pérez</name><affiliation><nlm:affiliation>Intensive Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="L Pez, Lissette Del Rosario" sort="L Pez, Lissette Del Rosario" uniqKey="L Pez L" first="Lissette Del Rosario" last="L Pez">Lissette Del Rosario L Pez</name><affiliation><nlm:affiliation>Intensive Medicine Department, Juan Manuel Marquez Pediatric Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Mezquia, Natacha" sort="Mezquia, Natacha" uniqKey="Mezquia N" first="Natacha" last="Mezquia">Natacha Mezquia</name><affiliation><nlm:affiliation>Intensive Medicine Department, Miguel Enríquez Surgical Clinical Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Venegas, Rafael" sort="Venegas, Rafael" uniqKey="Venegas R" first="Rafael" last="Venegas">Rafael Venegas</name><affiliation><nlm:affiliation>Intensive Medicine Department, Luis Díaz Soto Central Military Hospital, Havana, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Betancourt, Julio Roberto" sort="Betancourt, Julio Roberto" uniqKey="Betancourt J" first="Julio Roberto" last="Betancourt">Julio Roberto Betancourt</name><affiliation><nlm:affiliation>Intensive Medicine Department, Manuel Piti Fajardo Surgical Clinical Military Hospital, Villa Clara, Cuba.</nlm:affiliation></affiliation></author><author><name sortKey="Dominguez, Rodolfo Emilio" sort="Dominguez, Rodolfo Emilio" uniqKey="Dominguez R" first="Rodolfo Emilio" last="Domínguez">Rodolfo Emilio Domínguez</name><affiliation><nlm:affiliation>Intensive Medicine Department, Octavio de la Concepcion y la Pedraja Military Hospital. Camagüey, Cuba.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research</title><idno type="eISSN">1557-7465</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Chloroquine (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (mortality)</term><term>Cuba (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Interferon-alpha (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (mortality)</term><term>Prospective Studies (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Chloroquine</term><term>Interferon-alpha</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Cuba</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Prospective Studies</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus disease 2019 (COVID-19) outbreak began in Cuba. From March 11th to April 14th, 814 patients were confirmed SARS-CoV-2 positive in Cuba. Seven hundred sixty-one (93.4%) were treated with a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-α2b (Heberon<sup>®</sup> Alpha R, Center for Genetic Engineering and Biotechnology, Havana, Cuba), 3 times per week, for 2 weeks. Fifty-three patients received the approved COVID protocol without IFN treatment. The proportion of patients discharged from hospital (without clinical and radiological symptoms and nondetectable virus by real-time polymerase chain reaction) was higher in the IFN-treated compared with the non-IFN treated group (95.4% vs. 26.1%, <i>P</i> < 0.01). The case fatality rate (CFR) for all patients was 2.95%, and for those patients who received IFN-α2b the CFR was reduced to 0.92. Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-α2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32960147</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-7465</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research</Title><ISOAbbreviation>J Interferon Cytokine Res</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.</ArticleTitle><Pagination><MedlinePgn>438-442</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/jir.2020.0124</ELocationID><Abstract><AbstractText>A prospective observational study was conducted for assessing the therapeutic efficacy of interferon (IFN)-α2b in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first month after the coronavirus disease 2019 (COVID-19) outbreak began in Cuba. From March 11th to April 14th, 814 patients were confirmed SARS-CoV-2 positive in Cuba. Seven hundred sixty-one (93.4%) were treated with a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-α2b (Heberon<sup>®</sup> Alpha R, Center for Genetic Engineering and Biotechnology, Havana, Cuba), 3 times per week, for 2 weeks. Fifty-three patients received the approved COVID protocol without IFN treatment. The proportion of patients discharged from hospital (without clinical and radiological symptoms and nondetectable virus by real-time polymerase chain reaction) was higher in the IFN-treated compared with the non-IFN treated group (95.4% vs. 26.1%, <i>P</i> < 0.01). The case fatality rate (CFR) for all patients was 2.95%, and for those patients who received IFN-α2b the CFR was reduced to 0.92. Intensive care was required for 82 patients (10.1%), 42 (5.5%) had been treated with IFN. This report provides preliminary evidence for the therapeutic effectiveness of IFN-α2b for COVID-19 and suggests that the use of Heberon Alpha R may contribute to complete recovery of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereda</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Medical College of Havana, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Pedro Kouri Institute, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivero</LastName><ForeName>Hubert Blas</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivero</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Miguel Enríquez Surgical Clinical Hospital, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez</LastName><ForeName>Albadio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López</LastName><ForeName>Lissette Del Rosario</ForeName><Initials>LDR</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Juan Manuel Marquez Pediatric Hospital, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mezquia</LastName><ForeName>Natacha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Miguel Enríquez Surgical Clinical Hospital, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venegas</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Luis Díaz Soto Central Military Hospital, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betancourt</LastName><ForeName>Julio Roberto</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Manuel Piti Fajardo Surgical Clinical Military Hospital, Villa Clara, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domínguez</LastName><ForeName>Rodolfo Emilio</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Intensive Medicine Department, Octavio de la Concepcion y la Pedraja Military Hospital. Camagüey, Cuba.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Interferon Cytokine Res</MedlineTA><NlmUniqueID>9507088</NlmUniqueID><ISSNLinking>1079-9907</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000614170">Interferon-alpha2b</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003462" MajorTopicYN="N" Type="Geographic">Cuba</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-Cov-2</Keyword><Keyword MajorTopicYN="Y">interferon</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32960147</ArticleId><ArticleId IdType="doi">10.1089/jir.2020.0124</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000139 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32960147
|texte= Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32960147" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |